Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 103 full-time employees. The company went IPO on 2012-10-29. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The company develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
What is the price performance of Nanobiotix S.A. stock?
The current price of Nanobiotix S.A. is $52.88, it has increased 2.67% in the last trading day.
What are the primary business themes or industries for Nanobiotix SA?
Nanobiotix SA belongs to Biotechnology industry and the sector is Health Care
What is Nanobiotix SA market cap?
Nanobiotix SA's current market cap is $2.5B
Is Nanobiotix SA a buy, sell, or hold?
According to wall street analysts, 8 analysts have made analyst ratings for Nanobiotix SA, including 5 strong buy, 6 buy, 1 hold, 0 sell, and 5 strong sell